Aldosterone blockade: an emerging strategy for abrogating progressive renal disease

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Endocrinology

Background:

• Aldosterone is increasingly recognized as a key factor in progressive renal disease and heart failure, alongside angiotensin II.
• Previous research extensively documented angiotensin II's role, but recent evidence highlights aldosterone's significant pathogenetic contribution.

Purpose of the Study:

• To review the role of aldosterone in progressive renal dysfunction.
• To summarize evidence for aldosterone blockade in reducing proteinuria.
• To discuss therapeutic considerations for aldosterone blockade, including aldosterone escape and hyperkalemia.

Main Methods:

• Review of preclinical and clinical evidence on aldosterone blockade efficacy.
• Analysis of studies examining aldosterone escape and its clinical significance.
• Discussion of therapeutic strategies to mitigate hyperkalemia during aldosterone blockade.

Main Results:

• Aldosterone blockade demonstrates efficacy in abrogating proteinuria.
• Aldosterone escape is a recognized phenomenon with clinical importance.
• Therapeutic strategies exist to manage hyperkalemia associated with aldosterone blockade.

Conclusions:

• Aldosterone blockade is a potentially effective strategy for managing progressive renal dysfunction.
• Add-on aldosterone blockade may be a rational approach to retard renal disease progression, especially when current therapies are insufficient.
• New treatment algorithms incorporating aldosterone blockade could benefit patients with incipient nephropathy.